prednisone has been researched along with Micrometastases, Neoplasm in 1 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with newly-diagnosed M1a/b prostate cancer (PSMA PET/CT staging is permitted) and 1-5 radiographically visible metastases (excluding pelvic lymph nodes) are undergoing local treatment with radical prostatectomy, limited duration systemic therapy for a total of six months (leuprolide, abiraterone acetate with prednisone, and apalutamide), metastasis-directed stereotactic body radiotherapy (SBRT), and post-operative fractionated radiotherapy if pT ≥ 3a, N1, or positive margins are present." | 2.90 | Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. ( Aronson, WJ; Bennett, CJ; Garraway, IP; Gin, GE; Huiza, C; Inouye, WS; Jafari, L; Jordan, ML; Kalpage, N; Kishan, AU; Lee, SP; Lewis, M; Nickols, NG; Parikh, NR; Patel, JS; Pitcher, S; Reiter, RE; Rettig, MB; Sadeghi, A; Sanati, H; Thein, M; Tsai, S, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parikh, NR | 1 |
| Huiza, C | 1 |
| Patel, JS | 1 |
| Tsai, S | 1 |
| Kalpage, N | 1 |
| Thein, M | 1 |
| Pitcher, S | 1 |
| Lee, SP | 1 |
| Inouye, WS | 1 |
| Jordan, ML | 1 |
| Sanati, H | 1 |
| Jafari, L | 1 |
| Bennett, CJ | 1 |
| Gin, GE | 1 |
| Kishan, AU | 1 |
| Reiter, RE | 1 |
| Lewis, M | 1 |
| Sadeghi, A | 1 |
| Aronson, WJ | 1 |
| Garraway, IP | 1 |
| Rettig, MB | 1 |
| Nickols, NG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer[NCT03298087] | Phase 2 | 28 participants (Actual) | Interventional | 2018-07-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for prednisone and Micrometastases, Neoplasm
| Article | Year |
|---|---|
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2019 |